Invasive Bacterial Disease

Similar documents
Invasive Bacterial Disease

Chickenpox Death. West Virginia Electronic Disease Surveillance System

Pertussis. West Virginia Electronic Disease Surveillance System

Diphtheria. West Virginia Electronic Disease Surveillance System

Hepatitis Case Investigation

Of 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were

Streptococcus pneumoniae CDC

Incidence per 100,

Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014

IMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:

Influenza-Associated Pediatric Deaths Case Report Form

Incidence per 100,000

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015

Haemophilus influenzae

Source: Portland State University Population Research Center (

BOTULISM INVESTIGATION FORM

Pneumococcal Disease and Pneumococcal Vaccines

Streptococcus Pneumoniae

2.3 Invasive Group A Streptococcal Disease

OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine

Multi-drug Resistant Serotype 19A Pneumococci in Toronto

continuing education for pharmacists

Haemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)

9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria

Haemophilus influenzae, Invasive Disease rev Jan 2018

Demographics and Health Data

Demographics and Health Data

GROUP A STREPTOCOCCUS (GAS) INVASIVE

Group B Streptococcus

INVASIVE PNEUMOCOCCAL DISEASE IN NEW ZEALAND, Helen Heffernan. Julie Morgan. Rosemary Woodhouse. Diana Martin

Pneumococcal 13-valent Conjugate Vaccine Biological Page

Flu & Pneumonia Provider Toolkit

Appendix B: Provincial Case Definitions for Reportable Diseases

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle

ESRD Dialysis Prevalence - One Year Statistics

Streptococcus pneumoniae

INVASIVE PNEUMOCOCCAL DISEASE IN NEW ZEALAND, 2015

16 November 2017 National Immunisation Advisory Committee Recommendations for the 2017/2018 Influenza Vaccination Campaign

The Role of the Pharmacist in Pneumococcal Vaccination

Quick Reference Guide CAT4. Adult Immunisation

Tuberculosis in Chicago 2007

Surveillance of invasive pneumococcal infection in Belgium

Evelyn A. Kluka, MD FAAP November 30, 2011

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

EARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance

Pneum It's Your Health.

41 Pneumococcal Disease

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

Salt Lake County Annual Influenza Report Season Bureau of Epidemiology

PATIENT DEMOGRAPHICS. Surname. Given name. Pacific Islander (non-maori) ADMISSION DETAILS

ORIGINAL ARTICLE /j x

Policy and Procedure Manual

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

Patient Interview Form

2016 Pharmacist Re-Licensure Survey Instrument

Arctic Council Ministerial April 2009

To view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults

Expanded Use of PCV13 & PPV23

Group B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,.

Welcome to Medina Family Chiropractic and Acupuncture!

Immunization of Specific Populations (Immunosuppressed and Chronic Health Conditions)

Pneumococcal vaccines

Getting national guidelines into practice: It takes more than education

Table 1 23 Pneumococcal Capsular Types Included in PNEUMOVAX 23

Tuberculosis in Chicago 2006

Adult Demographics Form

Invasive Bacterial Diseases in the Arctic. Tom Hennessy, MD, MPH Arctic Investigations Program October 2, 2015 Copenhagen

KAREN J. SUNDBY, M.D. PLEASE COMPLETE THE FOLLOWING MEDICAL HISTORY FORM

Vaccines for Primary Care Pneumococcal, Shingles, Pertussis

UKnowledge. University of Kentucky

Rethinking Recommendations for Use of Pneumococcal Vaccines in Adults

HAEMOPHILUS INFLUENZAE INVASIVE DISEASE

Update on Adult Immunization Strategies: Understanding the Current Recommendations

Alzheimer Disease Research Center

Serotype Distribution and Antimicrobial Resistance of

Dr.Mohammed Al-Araji 2015/2016 Streptococcus pneumoniae

Federation of State Boards of Physical Therapy Minimum Data Set Questionnaire

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

TABLE OF CONTENTS 1.0 CLINICAL INFORMATION EPIDEMIOLOGY... 2

Updates on H. pylori research in Alaska. Bethel, Alaska, July 26 th 2016 Michael Bruce MD, MPH AIP/CDC, Anchorage, Alaska

Pneumococcal Vaccines. What s right for your clients?

EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002

Notto Chiropractic Health Center Patient Information

Mailing Address: Street City Zip

Deaths in Hawaii Due to Major Cardiovascular Disease

Objectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children

Annual Epidemiological Report

11/17/2013 THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS. Pneumococcal Vaccines for Adults (PPV) Pneumococcal Vaccines

PNEUMOVAX 23 pneumococcal vaccine, polyvalent solution for injection

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

The Muscatine Study Heart Health Survey

Elements for a Public Summary

Transcription:

Invasive Bacterial Disease All Streptococcus pneumoniae Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program : 304-558-5358 or 800-423-1271 in Fax: 304-558-8736 * indicates required fields Disease Under Investigation (Bacterial species isolated from any normally sterile site) Drug Resistant Streptococcus pneumoniae ('Pneumococcus') Streptococcus pneumoniae in children less than age 5 Streptococcus pneumoniae, all other Investigation Status* Closed Open Regional Review State Review Superceded Unassigned Case Status* Confirmed Not a Case Probable Suspect Unknown Patient Information * indicates required fields Last Name* First Name* Middle Initial Street Address City County State Zip Is the patient's residence a: Correctional Facility (Specify) Shelter or Group Home (Specify) Home Long Term Care Facility (Specify) None of the above Other Report Date Parent / Guardian Information Last Name First Name Middle Initial Relationship to Patient Check if address is same as above; otherwise complete guardian contact information below Guardian Street Address City County State Zip Home Other

First Name Last Name Invasive Bacterial Disease 11/14/2004 Page 2 Patient Demographic Information * indicates required fields Sex Male Female Transsexual Unknown Failure to report sex/missing sex Other (Specify) Date of Birth* Age Age Units Days Weeks Months Years Ethnicity Hispanic or Latino Not Hispanic or Latino Unknown Failure to report ethnicity/missing ethnicity Race American Indian or Alaska Native Black or African American White Failure to report race/missing race Date of onset of symptoms Asian Native Hawaiian or Other Pacific Islander Unknown Some Other Race Outcome and Clinical Information Date of diagnosis Was the patient hospitalized for the disease? Name of Hospital Date of Admission Patient outcome from this disease: Died Survived Unknown Date of Death Types of infection caused by organism Abscess (not skin) Bacteremia without focus Cellulitis Chorioamnionitis Endometritis Epiglottitis Hemolytic Uremic Syndrome (HUS) Meningitis Necrotizing fasciitis Osteomyelitis Otitis media Pericarditis Peritonitis Pneumonia Puerperal sepsis Septic abortion Septic arthritis STSS Other (specify) Laboratory Results Sterile sites from which the organism was isolated: Blood Bone CSF Internal body site: (specify) Joint Muscle Pericardial fluid Peritoneal fluid Pleural fluid Other normally sterile site: (specify) Date first positive culture obtained Other sites from which organism isolated: Amniotic fluid Middle ear Placenta Sinus Wound Other: Laboratory Name Fax Number Address State: Zip:

First Name Last Name Invasive Bacterial Disease 11/14/2004 Page 3 Oxacillin zone size (valid 00-30mm) Oxacillin Disk Susceptibility Testing Results Oxacillin interpretation R<20 (possibly resistant) S>=20 (susceptible) Unknown; not tested

First Name Last Name Invasive Bacterial Disease 11/14/2004 Page 4 Minimum Inhibitory Concentration (MIC) Susceptibility Testing Results Antimicrobial Agent Susceptibility Method S/I/R/U Result Sign** MIC Value A=Agar dilution method B=Broth dilution D=Disk diffusion (Kirby Bauer) S=Strip: Antimicrobial gradient strip (E-test) Result indicates microorganism's susceptibility to the antimicrobial being tested Select Sign (e.g., 0.06 ug/ml) PENICILLIN AMOXICILLIN AMOXICILLIN+CLAVULANATE CEFOTAXIME CEFTRIAXONE CEFUROXIME VANCOMYCIN ERYTHROMYCIN AZITHROMYCIN TETRACYCLINE LEVOFLOXACIN SPARFLOXACIN GATIFLOXACIN MOXIFLOXACIN TRIMETHOPRIM+SULFAMETHOXAZOLE CLINDAMYCIN QUINUPRISTIN+DALFOPRISTIN LINEZOLID OTHER 1 (Specify Below) OTHER 2 (Specify Below) Record Other Antimicrobial Agent 1 Record Other Antimicrobial Agent 2 ** Note: Indicates whether the MIC is >,<,=,<=,>= to the numerical MIC value in the last column

First Name Last Name Invasive Bacterial Disease 11/14/2004 Page 5 Last Name Reporting Source First Name Fax Facility Address City State Zip E-mail Last Name Provider with Further Patient Information First Name Fax Address City State Zip Public Health Investigation Name of Person Interviewed Relationship to Patient Date reported to public health Investigator Date public health investigation began Health Department Investigation ID Part of an Outbreak? Outbreak Name Lost to follow-up? Yes No Check if epi-linked to another case and complete information below Last Name of Epi-linked Case First Name DOB County Onset Date

First Name Last Name Invasive Bacterial Disease 11/14/2004 Page 6 If none or information not available, check here: None Unknown Indicate underlying causes or prior illness AIDS or CD4 count < 200 Hodgkin's disease Alcohol abuse Immunoglobulin deficiency Asthma Immunosuppressive therapy (steroids, chemotherapy, radiation) Atherosclerotic cardiovascular disease (ASCVD)/CAD IVDU Obesity Leukemia Cerebral Vascular Accident (CVA)/Stroke Multiple myeloma Cirrhosis/Liver failure Nephrotic syndrome Cochlear implant Renal failure / renal dialysis CSF leak (2 deg trauma/surgery) Sickle cell anemia Current smoker Splenectomy / asplenia Deaf/Profound hearing loss Systemic lupus erythematosus (SLE) Diabetes mellitus Transplant (specify): Emphysema/COPD Other malignancy (specify): Heart failure/chf Other prior illness (specify): HIV infection Complement Deficiency Complete for patients with invasive Streptococcus pneumoniae infection Has the patient received 23-valent pneumococcal polysaccharide vaccine? Vaccine Name? If Yes, list date most recently given? How many doses has the patient received? If < 15 years of age, did the patient receive pneumococcal conjugate vaccine? If Yes, complete the table below Dose Date given Vaccine Name Vaccine Manufacturer Lot Number 1. 2. 3. 4. What was the serotype? 1 2 3 4 5 6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F Not done Not vaccine strain (specify) Describe public health action taken Public Health Action Taken